This dual-immunotherapy neoadjuvant treatment regimen is mainly intended for patients with resectable stage IIB to III colon ...

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in patients with inflammatory bowel disease who have ulcerative colitis. The lack ...

The FDA has released a plan to stop or reduce the use of primates for testing the safety of certain monoclonal antibodies (mAbs), the latest expansion of the regulator’s efforts to eliminate animal ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

Dec 2 (Reuters) - The U.S. Food and Drug Administration on Tuesday issued new draft guidance on reducing the use of lab monkeys in preclinical toxicity studies for certain monoclonal antibodies. The ...

Triple-negative breast cancer (TNBC) is one of the hardest breast cancers to treat because it grows quickly, spreads early and often becomes resistant to therapy. In a new preclinical study, ...

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole while a clear bag slowly empties into a vein. A new generation of ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...